Michael B Clearfield
Overview
Explore the profile of Michael B Clearfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Preiss D, Campbell R, Murray H, Ford I, Packard C, Sattar N, et al.
Eur Heart J
. 2015 Mar;
36(24):1536-46.
PMID: 25802390
Aims: The effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish whether statins reduce major HF events. Methods And Results:...
2.
Boekholdt S, Hovingh G, Mora S, Arsenault B, Amarenco P, Pedersen T, et al.
J Am Coll Cardiol
. 2014 Aug;
64(5):485-94.
PMID: 25082583
Background: Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the consequence of this variability for cardiovascular disease risk is not well-documented. Objectives: The aim of this...
3.
Boekholdt S, Arsenault B, Hovingh G, Mora S, Pedersen T, LaRosa J, et al.
Circulation
. 2013 Aug;
128(14):1504-12.
PMID: 23965489
Background: It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density...
4.
Boekholdt S, Arsenault B, Mora S, Pedersen T, LaRosa J, Nestel P, et al.
JAMA
. 2012 Mar;
307(12):1302-9.
PMID: 22453571
Context: The associations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have...
5.
Clearfield M
J Am Osteopath Assoc
. 2010 May;
110(4 Suppl 4):S2-6.
PMID: 20453192
The role of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerosis is well recognized. Recent research has documented the importance of inflammation in atherosclerosis formation and disease progression. Lowering...
6.
Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, et al.
Lancet
. 2010 Feb;
375(9716):735-42.
PMID: 20167359
Background: Trials of statin therapy have had conflicting findings on the risk of development of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of published...
7.
Bray G, Clearfield M, Fintel D, Nelinson D
Clin Cornerstone
. 2009 Oct;
9(4):30-40.
PMID: 19789062
Obesity, particularly abdominal adiposity, is increasingly recognized as a cause of elevated cardiometabolic risk--the risk of developing type 2 diabetes mellitus (DM) and cardiovascular disease (CVD). The predominate mechanisms appear...
8.
Cui Y, Watson D, Girman C, Shapiro D, Gotto A, Hiserote P, et al.
Am J Cardiol
. 2009 Sep;
104(6):829-34.
PMID: 19733719
Reducing low-density lipoprotein (LDL) cholesterol with statins reduces cardiovascular risk, but the associations between increases in high-density lipoprotein (HDL) cholesterol and cardiovascular risk at different LDL levels have been less...
9.
10.
Licciardone J, Clearfield M, Guillory V
Acad Med
. 2009 May;
84(6):744-50.
PMID: 19474550
Purpose: To explore characteristics of patient visits to osteopathic physicians (DOs) and allopathic physicians (MDs) in the provision of ambulatory primary care services at academic health centers (AHCs) relative to...